Inactive Instrument

Fibrocell Science, Inc.

US3157214079

Biotechnology & Medical Research

Fibrocell Science, Inc. Announces Resignation of Michael F. Marino as Senior Vice President, General Counsel and Corporate Secretary

January 26, 2017 at 09:38 pm

Fibrocell Science, Inc. announced that on January 25, 2017 Michael F. Marino, Esq. resigned as the company's Senior Vice President, General Counsel and Corporate Secretary, effective immediately.

Latest news about Fibrocell Science, Inc.

Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from S&P TMI Index	16/12/19	CI
Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from NASDAQ Composite Index	13/12/19	CI
Castle Creek Pharmaceutical Holdings, Inc. completed the acquisition of Fibrocell Science, Inc..	12/12/19	CI
Fibrocell Science, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	14/11/19	CI
Castle Creek Pharmaceutical Holdings, Inc. entered into a definitive agreement to acquire Fibrocell Science, Inc. for $63.3 million.	11/09/19	CI
Fibrocell Science, Inc Appoints Sean D. Buckley as Chief Financial Officer	22/08/19	CI
Fibrocell Science, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	14/08/19	CI
Fibrocell Science, Inc. Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB	29/05/19	CI
Fibrocell Science, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	15/05/19	CI
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy	15/04/19	CI
Fibrocell Science, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	27/03/19	CI
Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007	27/03/19	CI
Fibrocell Science, Inc. Auditor Raises 'Going Concern' Doubt	26/03/19	CI
Fibrocell Science, Inc. announced that it has received $0.9 million in funding from EB Research Partnership, Inc., Endowment Arm, Epidermolysis Bullosa Medical Research Foundation, Endowment Arm	10/12/18	CI
Fibrocell Science, Inc. announced that it expects to receive $0.9 million in funding from EB Research Partnership, Inc., Endowment Arm, Epidermolysis Bullosa Medical Research Foundation, Endowment Arm	06/12/18	CI
Fibrocell Science, Inc. Reports Consolidated Unaudited Earnings Results for the Nine Months Ended September 30, 2018	13/11/18	CI
Fibrocell Science, Inc. Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007	25/10/18	CI
Fibrocell Science, Inc. Announces U.S. Food and Drug Administration Granted Fast Track Designation to FCX-013	05/09/18	CI
Fibrocell Science, Inc. Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018; Expects to Enroll A Total of Six Patients Ages Seven and Older by the End of the Third Quarter of 2018	09/08/18	CI
Fibrocell Science, Inc. announced that it has received $0.119769 million in funding	04/07/18	CI
Fibrocell Science, Inc. announced that it expects to receive $0.119769 million in funding	01/07/18	CI
Fibrocell Science, Inc. Appoints Sean D. Buckley as Vice President of Business Administration and Corporate Secretary	22/06/18	CI
Fibrocell Science, Inc. announced that it has received $0.191084 million in funding	30/05/18	CI
Fibrocell Science, Inc. announced that it expects to receive $0.191084 million in funding	28/05/18	CI
Fibrocell Science, Inc. Provides an Update on Interim Results and Progress of its Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa	21/05/18	CI

Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research